Showing 4561-4570 of 5348 results for "".
- Vanda's Tradipitant Improves Itch and Disease Severity in AD Patientshttps://practicaldermatology.com/news/vandas-tradipitant-improves-itch-and-disease-severity-in-ad-patients/2458053/Vanda Pharmaceuticals Inc.’s tradipitant improved the intensity of the worst itch patients experienced, as well as atopic dermatitis (AD) disease severity, according to results from an eight-week randomized Phase 2 clinical. Tradipitant
- IPC, Others Call for Creation of Worldwide Psoriasis Databasehttps://practicaldermatology.com/news/ipc-others-call-for-creation-of-worldwide-psoriasis-database/2458055/A new report calls for the creation of a web-based Global Psoriasis Atlas (GPA) database that will document the prevalence and incidence of psoriasis worldwide. The report, entitled "Global State of Psoriasis Epidemiology: A Workshop Report,
- Allergan Adds Coolsculpting, Other Bells and Whistles to Brilliant Distinctions® Patient Loyalty Programhttps://practicaldermatology.com/news/allergan-adds-coolsculpting-other-bells-and-whistles-to-brilliant-distinctions-patient-loyalty-program/2458056/Allergan is launching the next generation of its U.S.-based Brilliant Distinctions® program. The new offering incorporates digital innovation to enhance the consumer experience and drive increased member engagement. In addition
- DermTech Appoints Dr. Gerald Krueger to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-appoints-dr-gerald-krueger-to-scientific-advisory-board/2458059/DermTech, Inc. has appointed Gerald G. Krueger, MD, to its Scientific Advisory Board. Dr. Krueger is Professor of Dermatology and Edna Benning Presidential Endowed Chair at the University of Utah in Salt Lake City, UT. He received his m
- Two Galderma Rosacea Therapies Work Well Togetherhttps://practicaldermatology.com/news/two-galderma-rosacea-therapies-work-well-together/2458061/Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCe
- Link Found Between a Molecular Driver of Melanoma Progression and Novel Therapeutic Agenthttps://practicaldermatology.com/news/link-found-between-a-molecular-driver-of-melanoma-progression-and-novel-therapeutic-agent/2458065/Research linking autophagy with the Wnt signaling pathway, a key regulator of melanoma progression and metastasis, may guide effective use of autophagy inhibitors. The findings appear online in Cancer Research. Autophagy allows cancer cells to survive under stressful cond
- AD Breakthrough? Medimetriks' MM36 Achieves Rapid Itch Relief, Safety in Phase 2 Studyhttps://practicaldermatology.com/news/ad-breakthrough-medimetriks-mm36-achieves-rapid-itch-relief-safety-in-phase-2-study/2458068/Medimetriks’ PDE4 inhibitor, MM36, appears to be safe, well-tolerated and provides rapid itch relief when applied twice daily to pediatric and adolescent atopic dermatitis (AD) patients, according to results of a Phase 2 study. The company ex
- Skin Color Affects Skin Sensitivity to Heat and Mechanical Stimulihttps://practicaldermatology.com/news/skin-color-affects-skin-sensitivity-to-heat-and-mechanical-stimuli/2458069/Researchers at the Bluestone Center for Clinical Research at the New York University College of Dentistry (NYU Dentistry) have identified a novel molecular mechanism which explains why dark-skinned and light-skinned people respond differently to heat and mechanical stimulation. In a study
- Kyocera Begins Research in AI-based Image Recognition to Help Diagnose Skin Diseases and Cancers Via Smartphonehttps://practicaldermatology.com/news/kyocera-begind-research-in-ai-based-image-recognition-to-help-diagnose-skin-diseases-and-cancers-via-smartphone/2458070/Kyocera Corporation is partnering with the University of Tsukuba to develop Artificial Intelligence (AI)-based image recognition for eHealth applications to diagnose melanoma and other skin diseases by analyzing digital images of a patient’s skin.
- GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologicshttps://practicaldermatology.com/news/gbi-research-global-dermatology-pipeline-to-see-shift-toward-increased-use-of-biologics/2458071/The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of the pipeline dominated by generics and biosimilars, according to GBI Research. The company